NewAmsterdam Pharma Company (NAMS) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

NewAmsterdam Pharma Company Revenue Highlights


Latest Revenue (Y)

$14.09M

Latest Revenue (Q)

$1.40M

Main Segment (Y)

License Revenue

NewAmsterdam Pharma Company Revenue by Period


NewAmsterdam Pharma Company Revenue by Year

DateRevenueChange
2023-12-31$14.09M-85.55%
2022-12-31$97.50M100.00%
2021-12-31-100.00%
2020-12-31--

NewAmsterdam Pharma Company generated $14.09M in revenue during NA 2023, up -85.55% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

NewAmsterdam Pharma Company Revenue by Quarter

DateRevenueChange
2024-03-31$1.40M-20.51%
2023-06-30$1.76M-79.58%
2023-03-31$8.63M-91.15%
2022-12-31$97.50M100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

NewAmsterdam Pharma Company generated $1.40M in revenue during Q1 2024, up -20.51% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

NewAmsterdam Pharma Company Revenue Breakdown


NewAmsterdam Pharma Company Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22
License Revenue$97.50M

NewAmsterdam Pharma Company's latest annual revenue breakdown by segment (product or service), as of Dec 22: License Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 23
License Revenue$4.56M

NewAmsterdam Pharma Company's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License Revenue (100.00%).

NewAmsterdam Pharma Company Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
MRUSMerus$43.95M$11.77M
IVAInventiva$17.50M$15.58M
NAMSNewAmsterdam Pharma Company$14.09M$1.40M
JANXJanux Therapeutics$8.08M$1.25M
MOLNMolecular Partners$7.04M$2.74M
CRNXCrinetics Pharmaceuticals$4.01M$640.00K
PRTCPureTech Health$3.33M$178.57K
ANEBAnebulo Pharmaceuticals--
CGEMCullinan Oncology--
RZLTRezolute--
REPLReplimune Group--
CYTCyteir Therapeutics--
ELYMEliem Therapeutics--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
CMPXCompass Therapeutics--
PEPGPepGen--

NAMS Revenue FAQ


NewAmsterdam Pharma Company's yearly revenue for 2023 was $14.09M, representing a decrease of -85.55% compared to 2022. The company's yearly revenue for 2022 was $97.5M, representing an increase of 100.00% compared to 2021. NAMS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

NewAmsterdam Pharma Company's quarterly revenue for Q1 2024 was $1.4M, a -20.51% decrease from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $1.76M, a -79.58% decrease from the previous quarter (Q1 2023), and a 0% increase year-over-year (Q2 2022). NAMS's quarterly revenue for Q1 2023 was $8.63M, a -91.15% decrease from the previous quarter (Q4 2022), and a 0% increase year-over-year (Q1 2022).

NewAmsterdam Pharma Company's revenue growth rate for the last 3 years (2021-2023) was 0%

NewAmsterdam Pharma Company's revenue streams in c 22 are License Revenue

For the fiscal year ending Dec 22, the largest source of revenue of NewAmsterdam Pharma Company was License Revenue. This segment made a revenue of $97.5M, representing 100.00% of the company's total revenue.